This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
LDHA · Western blot design guide
LDHA Western Blot Planning Guide
Plan a LDHA Western blot around the catalog-observed 36.7 kDa band, image-backed PB10075 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
LDHA Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 36.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Adipose tissue | |
| Negative control | Heart muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 36.7 kDa |
| ⓘ | Localization | Cytoplasm |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated LDHA Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB10075 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected LDHA Western Blot Band Size?
Use the product-observed 36.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 36.7 kDa | Matches the authoritative product WB observation. |
| 36.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected LDHA appearancePlan around 36.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 36.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 36.7 kDa from UniProt P00338; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB10075. |
| Situation | Likely cause | Next action |
|---|---|---|
| 36.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing LDHA band
PB10075 · LDHA
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for LDHA Western blot
🧪Use Adipose tissue as the first positive-control candidate and Heart muscle as the HPA Not detected negative candidate.
Positive control: Adipose tissue (Medium)
Negative control: Heart muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for LDHA
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced LDHA Western Blot Tips
Deeper troubleshooting and optimisation questions for LDHA, answered from its protein features.
Which band should guide the blot?
Use 36.7 kDa, the observation attached to the authoritative PB10075 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 36.7 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Heart muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for LDHA Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB10075 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
LDHA Western Blot Reagents
Human/Mouse/Rat-reactive LDHA Western blot reagents with authoritative product imagery.
Real WB data
Anti-LDHA Antibody Picoband®
Cat # PB10075
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P00338
- Human Protein Atlas — LDHA
- PB10075 product record
- PMC12224598 — Amino acid transporter LAT1 (SLC7A5) promotes metabolic rewiring in TNBC progression through the L-Trp/QPRT/NAD(+) pathway (Journal of experimental & clinical cancer research : CR, 2025)
- PMC5454382 — Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation (Nature communications, 2017)
- PMC8960958 — Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis (Frontiers in oncology, 2022)